Structure-activity relationships of adenosines with heterocyclic N6-substituents

被引:34
作者
Ashton, T. D. [1 ]
Aumann, Kylee M. [2 ,3 ]
Baker, Stephen P. [4 ]
Schiesser, Carl H. [2 ,3 ]
Scammells, Peter J. [1 ]
机构
[1] Monash Univ, Victorian Coll Pharm, Dept Med Chem, Parkville, Vic 3052, Australia
[2] Univ Melbourne, Sch Chem, Melbourne, Vic 3010, Australia
[3] Univ Melbourne, Bio21 Mol Sci & Biotechnol Inst, Melbourne, Vic 3010, Australia
[4] Univ Florida, Coll Med, Dept Pharmacol & Therapeut, Gainesville, FL 32610 USA
基金
澳大利亚研究理事会;
关键词
adenosine; A(1)AR agonist;
D O I
10.1016/j.bmcl.2007.10.028
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Two series of N-6-substituted adenosines with monocyclic and bicyclic N-6 substituents containing a heteroatom were synthesized in good yields. These derivatives were assessed for their affinity ([H-3]CPX), potency, and intrinsic activity (cAMP accumulation) at the A, adenosine receptor in DDT1 MF-2 cells. In the monocyclic series, the N-6-tetrahydrofuran-3-yl and thiolan-3-yl adenosines (1 and 26, respectively) were found to possess similar activities, whereas the corresponding selenium analogue 27 was found to be more potent. A series of nitrogen containing analogues showed varying properties, N-6-((3R)-1-benzyloxycarbonylpyrrolidin-3-yl)adenosine (30) was the most potent at the AIAR; IC50 = 3.2 nM. In the bicyclic series, the effect of a 7-azabicyclo[2.2.1]heptan-2-yl substituent in the N-6-position was explored. N6- (7-Azabicyclo[2.2.1] heptan-2-yl)adeno sine (38) proved to be a reasonably potent A, agonist (K-i = 51 nM, IC50 = 35 nM) while further substitution on the 7 ''-nitrogen with tert-butoxycarbonyl (31, IC50 = 2.5 nM) and 2-bromobenzyloxycarbonyl (34, IC50 = 9.0 nM) gave highly potent A(1)AR agonists. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:6779 / 6784
页数:6
相关论文
共 24 条
[1]   Structure-activity relationships of 2,N6,5′-substituted adenosine derivatives with potent activity at the A2B adenosine receptor [J].
Adachi, Hayamitsu ;
Palaniappan, Krishnan K. ;
Ivanov, Andrei A. ;
Bergman, Nathaniel ;
Gao, Zhan-Guo ;
Jacobson, Kenneth A. .
JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (08) :1810-1827
[2]   Synthesis and biological evaluation of novel N6-[4-(substituted) sulfonamidophenylcarbamoyl]adenosine-5′-uronamides as A3 adenosine receptor agonists [J].
Baraldi, PG ;
Fruttarolo, F ;
Tabrizi, MA ;
Romagnoli, R ;
Preti, D ;
Bovero, A ;
de Las Infantas, MJP ;
Moorman, A ;
Varani, K ;
Borea, PA .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (22) :5535-5540
[3]   Synthesis and biological evaluation of novel 1-deoxy-1-[6-[((hetero)arylcarbonyl)hydrazino]-9H-purin-9-yl]-N-ethyl-β-D-ribofuranuronamide derivatives as useful templates for the development of A2B adenosine receptor agonists [J].
Baraldi, Pier Giovanni ;
Preti, Delia ;
Tabrizi, Mojgan Aghazadeh ;
Fruttarolo, Francesca ;
Romagnoli, Romeo ;
Carrion, Maria Dora ;
Lopez Cara, Luisa Carlota ;
Moorman, Allan R. ;
Varani, Katia ;
Borea, Pier Andrea .
JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (02) :374-380
[4]   Fluorosulfonyl-substituted xanthines as selective irreversible antagonists for the A1-adenosine receptor [J].
Beauglehole, AR ;
Baker, SP ;
Scammells, PJ .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (26) :4973-4980
[5]   STRUCTURAL REQUIREMENTS OF NUCLEOSIDES FOR BINDING BY ADENOSINE DEAMINASE [J].
CORY, JG ;
SUHADOLNIK, RJ .
BIOCHEMISTRY, 1965, 4 (09) :1729-+
[6]  
DEHMLOW EV, 1992, SYNTHESIS-STUTTGART, P947
[7]   Pharmacology and therapeutic applications of A1 adenosine receptor ligands [J].
Dhalla, AK ;
Shryock, JC ;
Shreeniwas, R ;
Belardinelli, L .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2003, 3 (04) :369-385
[8]   New, optically active phosphine oxazoline (JM-Phos) ligands: Syntheses and applications in allylation reactions [J].
Hou, DR ;
Reibenspies, JH ;
Burgess, K .
JOURNAL OF ORGANIC CHEMISTRY, 2001, 66 (01) :206-215
[9]   New potent and selective A1 adenosine receptor agonists [J].
Hutchinson, SA ;
Baker, SP ;
Linden, J ;
Scammells, PJ .
BIOORGANIC & MEDICINAL CHEMISTRY, 2004, 12 (18) :4877-4884
[10]   A1 adenosine receptor agonists:: Medicinal chemistry and therapeutic potential [J].
Hutchinson, SA ;
Scammells, PJ .
CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (17) :2021-2039